IDYA
Ideaya Biosciences IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Mid-Cap Blend
$31.24+1.92%
Close Nov 6, 2026
- Market cap
- $2.74B
- 1 month
- -13.4%
- 3 months
- -15.0%
- 1 year
- +5.3%
- 52-week range
- $27.60$42.48
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$1.16Quarter to Sep 30, 2026 · 14 analysts · revenue $7.58M · +0.1% in 30d
- Short interest
- 10.0% of float9.1M shares · settled Oct 15, 2026 · -1.1% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $234.13M
- Net income
- -$175.02M
- Free cash flow
- -$113.87M
- Book value
- $1.2B
- Total debt
- $29.31M
- P/E
- —
- Price / sales
- 11.7×
- Price / book
- 2.3×
- FCF yield
- -4.1%
- Net margin
- -74.8%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Read more
The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Website
- ideayabio.com
- Headquarters
- South San Francisco, CA, United States
- Employees
- 145
- Listed
- May 23, 2019
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 5, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 4, 2026 | $8.9M | — | 100.0% | -$122.3M | -$112.5M |
| Mar 2026filed May 5, 2026 | $6.6M | — | — | -$108.5M | -$98.5M |
| Dec 2025filed Feb 17, 2026 | $10.9M | +55.4% | — | -$94.6M | -$83.3M |
| Sep 2025filed Nov 4, 2025 | — | — | — | — | — |
| Jun 2025filed Aug 5, 2025 | — | — | — | -$88.8M | -$77.5M |
| Mar 2025filed May 6, 2025 | — | — | — | -$84.4M | -$72.2M |
| Dec 2024filed Feb 18, 2025 | $7.0M | +78.4% | — | -$144.1M | -$130.3M |
| Sep 2024filed Nov 4, 2024 | — | — | — | -$66.9M | -$51.8M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 17, 2026 | $218.7M | +3,024.4% | -43.9% | -$159.3M | -$113.7M |
| Dec 2024filed Feb 18, 2025 | $7.0M | -70.1% | 45.2% | -$327.0M | -$274.5M |
| Dec 2023filed Feb 20, 2024 | $23.4M | -54.1% | 82.9% | -$134.4M | -$113.0M |
| Dec 2022filed Mar 7, 2023 | $50.9M | +82.3% | — | -$62.5M | -$54.8M |
| Dec 2021filed Mar 18, 2022 | $27.9M | +43.0% | — | -$50.3M | -$47.5M |
| Dec 2020filed Mar 23, 2021 | $19.5M | — | — | -$35.3M | -$32.3M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched IDYA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
9,079,434 shares short
-103,783 shares (-1.1%) vs Sep 30, 2026
10% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
9,183,217 shares short
-748,405 shares (-7.5%) vs Sep 15, 2026
10.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
9,931,622 shares short
-172,135 shares (-1.7%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
10,103,757 shares short
-294,321 shares (-2.8%) vs Aug 14, 2026
11.6% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
10,398,078 shares short
+284,872 shares (+2.8%) vs Jul 31, 2026
12% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
10,113,206 shares short
+539,626 shares (+5.6%) vs Jul 15, 2026
11.6% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind IDYA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if IDYA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
43 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: sell 30 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
286 filers reported a long position in IDYA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
57.8%
of the 102.2M shares 13-F filers reported
Moves vs Q1 2026
7 added2 trimmed
1 not comparable
Net shares held
+9.6%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $525.9M · 14.1M shares | 14.1M | +7.1% |
| 2 | BlackRock, Inc. | $331.5M · 8.9M shares | 8.9M | +5.3% |
| 3 | Jupiter Topco LLC | $319.7M · 8.6M shares | 8.6M | — |
| 4 | Capital Research Global Investors | $199.2M · 5.3M shares | 5.3M | +3.5% |
| 5 | BAKER BROS. ADVISORS LP | $186.7M · 5M shares | 5M | +26.9% |
| 6 | STATE STREET CORP | $169.5M · 4.5M shares | 4.5M | +20.3% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $154M · 4.1M shares | 4.1M | +10.7% |
| 8 | Logos Global Management LP | $111.8M · 3M shares | 3M | -13% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $101.2M · 2.7M shares | 2.7M | -3.8% |
| 10 | DEERFIELD MANAGEMENT COMPANY, L.P. | $101.2M · 2.7M shares | 2.7M | +77.4% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of IDYA file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 14, 2026 | BAKER BROS. ADVISORS LP13G · passive | 5.2% |
| Jul 31, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.08% |
| May 15, 2026 | JANUS HENDERSON GROUP PLC13G · passive · amended | 8.3% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for IDYA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.